Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone - PubMed

Clinical Trial

Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone

T Brenner et al. J Neuroimmunol. 2001.

Abstract

Humoral and cellular immune responses were followed in multiple sclerosis patients treated with Copolymer 1 (Cop1, glatiramer acetate, Copaxone) who participated in three different clinical trials. All patients (130) developed Cop1 reactive antibodies, which peaked at 3 months after initiation of treatment, decreasing at 6 months and remaining low. IgG1 antibody levels were 2-3-fold higher than those of IgG2. The proliferative response of Peripheral Blood Mononuclear Cells (PBMC) to Cop1 was initially high and gradually decreased during treatment. Antibodies and T cell responses to MBP were low and did not change significantly during the treatment. The humoral and cellular immunological responses to Cop1 do not correlate with the side effects and do not affect its therapeutic activity. The preferential production of IgG1 over IgG2 antibodies may indicate that Th2 responses are involved in mediating the clinical effect of Cop1.

Similar articles

• Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients.

  Qin Y, Zhang DQ, Prat A, Pouly S, Antel J. Qin Y, et al. J Neuroimmunol. 2000 Aug 1;108(1-2):201-6. doi: 10.1016/s0165-5728(00)00263-0. J Neuroimmunol. 2000. PMID: 10900354

• Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.

  Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA. Duda PW, et al. J Clin Invest. 2000 Apr;105(7):967-76. doi: 10.1172/JCI8970. J Clin Invest. 2000. PMID: 10749576 Free PMC article. Clinical Trial.

• Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients.

  Farina C, Vargas V, Heydari N, Kümpfel T, Meinl E, Hohlfeld R. Farina C, et al. J Neuroimmunol. 2002 Feb;123(1-2):188-92. doi: 10.1016/s0165-5728(01)00490-8. J Neuroimmunol. 2002. PMID: 11880163

• Immunomodulatory vaccines against autoimmune diseases.

  Sela M. Sela M. Rejuvenation Res. 2006 Spring;9(1):126-33. doi: 10.1089/rej.2006.9.126. Rejuvenation Res. 2006. PMID: 16608409 Review.

• The mechanism of action of glatiramer acetate treatment in multiple sclerosis.

  Racke MK, Lovett-Racke AE, Karandikar NJ. Racke MK, et al. Neurology. 2010 Jan 5;74 Suppl 1:S25-30. doi: 10.1212/WNL.0b013e3181c97e39. Neurology. 2010. PMID: 20038760 Review.

Cited by

• Clinical utility of glatiramer acetate in the management of relapse frequency in multiple sclerosis.

  Fernández O. Fernández O. J Cent Nerv Syst Dis. 2012 Aug 29;4:117-33. doi: 10.4137/JCNSD.S8755. Print 2012. J Cent Nerv Syst Dis. 2012. PMID: 23650472 Free PMC article.

• Interferon beta and glatiramer acetate therapy.

  McGraw CA, Lublin FD. McGraw CA, et al. Neurotherapeutics. 2013 Jan;10(1):2-18. doi: 10.1007/s13311-012-0163-4. Neurotherapeutics. 2013. PMID: 23264098 Free PMC article. Review.

• Immunoregulation of Theiler's virus-induced demyelinating disease by glatiramer acetate without suppression of antiviral immune responses.

  Omura S, Sato F, Martinez NE, Range T, Ekshyyan L, Minagar A, Alexander JS, Tsunoda I. Omura S, et al. Arch Virol. 2018 May;163(5):1279-1284. doi: 10.1007/s00705-018-3729-6. Epub 2018 Jan 23. Arch Virol. 2018. PMID: 29362931 Free PMC article.

• Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate.

  D Alessandro J, Garofalo K, Zhao G, Honan C, Duffner J, Capila I, Fier I, Kaundinya G, Kantor D, Ganguly T. D Alessandro J, et al. CNS Neurol Disord Drug Targets. 2017;16(6):714-723. doi: 10.2174/1871527316666170223162747. CNS Neurol Disord Drug Targets. 2017. PMID: 28240190 Free PMC article.

• N-acetyl-L-cysteine ameliorates the inflammatory disease process in experimental autoimmune encephalomyelitis in Lewis rats.

  Stanislaus R, Gilg AG, Singh AK, Singh I. Stanislaus R, et al. J Autoimmune Dis. 2005 May 3;2(1):4. doi: 10.1186/1740-2557-2-4. J Autoimmune Dis. 2005. PMID: 15869713 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal